Pfizer stock remains under pressure despite becoming one of the biggest names of the pandemic. Is PFE stock a sell?

The answer to that question will either make you wince or smile.

The firm has brought in as venture partner Uwe Schoenbeck, who most recently was the top scientist for Pfizer’s emerging science and innovation unit.

A modest amount of money can go a long way in the stock market when it's put to work in time-tested businesses with well-defined competitive advantages.

On Tuesday, Johnson & Johnson (NYSE: JNJ) delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost in line with estimates. First quarter results came shortly after JNJ’s expansion in the cardiovascular space with the $13.1 billion acquisition of heart device firm Shockwave Medical Inc (NASDAQ: SWAV). First Quarter Highlights For the period ended in March, the healthcare company posted a revenue

Pfizer (PFE) closed the most recent trading day at $25.91, moving +0.19% from the previous trading session.

The pharmaceutical giant is laying the groundwork for its next heyday.

The average yield from these stocks is more than five times the market average.

In this article, we will take a detailed look at the 10 Micro-Cap Healthcare Stocks Insiders Are Buying. For a quick overview of such stocks, read our article 5 Micro-Cap Healthcare Stocks Insiders Are Buying. Investors have always been interested in the connection between insider buying and stock returns. Over the past several years there’s been a huge influx […]

Alaska Permanent, the largest U.S. state wealth fund, tripled its investments in Walmart and Kroger.